Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib

Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib

Abstract Background Imatinib mesylate is an inhibitor of the tyrosine kinase Bcr–Abl and a first-line treatment for Philadelphia chromosome-positive chronic myeloid leukaemia (CML). Dermatological side effects include superficial oedema, pustular eruption, lichenoid reactions, erythroderma, and skin...

Full description

Bibliographic Details
Main Authors: Gian Paolo Bombeccari, Umberto Garagiola, Francesco Pallotti, Margherita Rossi, Massimo Porrini, Aldo Bruno Giannì, Francesco Spadari
Format: Article
Language:English
Published: SpringerOpen 2017-12-01
Series:Maxillofacial Plastic and Reconstructive Surgery
Subjects:
Chronic myeloid leukaemia
Oral melanosis
Drug-induced oral reactions
Oral pigmentation
Mucosal pigmentation
Online Access:http://link.springer.com/article/10.1186/s40902-017-0136-y

Internet

http://link.springer.com/article/10.1186/s40902-017-0136-y

Similar Items